Research programme: HN-1 peptide anticancer therapeutics - Tapestry Pharmaceuticals

Drug Profile

Research programme: HN-1 peptide anticancer therapeutics - Tapestry Pharmaceuticals

Alternative Names: HN-1 peptide delivery; HN-1 Taxane A proprietary synthetic peptide/paclitaxel conjugate

Latest Information Update: 19 Nov 2007

Price : $50

At a glance

  • Originator M. D. Anderson Cancer Center; Tapestry Pharmaceuticals
  • Class Taxanes
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Squamous cell cancer

Most Recent Events

  • 07 May 2004 NaPro Biotherapeutics is now called Tapestry Pharmaceuticals
  • 03 Apr 2003 Preclinical trials in Squamous cell cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top